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I. ITMRODUTION
Since the mid-1980s, scientists from all over the world have been
researching and analyzing the human genome. 1 Scientists affiliated
with the United States Department of Energy (DOE) and the National
Institute of Health (NIH) have led the United States' efforts in this
area of biomedical research.2 In 1985, the DOE began planning a
Human Genome Initiative with the following objectives: (1) to create
an ordered set of DNA segments from known chromosomal loca-
tions;' (2)to develop new computational methods by which to analyze
data;4 and (3) to find new ways of mapping genomes.5 The NIH has
supported genomic research with similar objectives since 1987.6
In 1991 and 1992, the NIH filed patent applications on thousands
of gene fragments that were sequenced using a technique developed
by one of its employees, Dr. J. Craig Venter, former chief of receptor
biochemistry at the National Institute of Neurological Disorders and
Stroke of the-NIH.7 The United States Patent and Trademark Office
(PTO) rejected the NIH's applications in 1992 and 1993, and the NIH
formally abandoned its applications on February 11, 1994.8
1. See generally Robert Mullan Cook-Deegan, Mapping the Human Genome, 65 S. CAL.
L. REv. 579, 579:-582 (1991) (describing the origins of the "political movement to organize
mapping and sequencing efforts."). "A genome is the "complete set of genes [of] an organism."
U.S. CoNGREsS, OFImcE oF TECHNoLoGY ASSESsMENT, MAPpINa OuR GENES - THE GENOME
PRoJECrS: How Bra, How FAST? 46 (1988) [hereinafter MAPPiNO OuR GENES].
2. MAPPiNa OuR GENEs, supra note 1, at 44.
3. Id. at 46.
4. Id.
5. Id at 47.
6. -Ld at 48.
I. Bernice Wuethrich, All Rights ReservedL How the gene-patenting Race is Affecting
Science, 144 ScL NEws 154, 155 (1993).
1 8. Michael Waldholz, Science: NIH Gives Up Effort to Patent Pieces of Genes, WA.L
ST.J., Feb. 11, 1994, at BI.
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The NIH's decision to abandon its application leaves open the
question of whether gene fragments may be patented under United
States patent law. 9 Private entities have not been dissuaded by the
PTO's ruling and have filed applications claiming patents on
thousands of gene fragments.10 Until there is a definitive ruling by the
Federal Circuit or by the United States Supreme Court on whether
gene fragments are patentable, it is likely that the PTO will receive
many more applications. In the meantime, researchers remain uncer-
tain of the patent law governing their research.
This comment recommends that Congress promote the continued
development of human genome research by clarifying whether certain
products of biotechnology are patentable. The comment is divided
into eight sections. Section I is this introduction. Section II of this
comment provides a scientific background on human genome re-
search. Section I describes Dr. Venter's research and the NIH's ra-
tionale for attempting to gain patents on gene fragments. Section IV
provides background on the goals of and the statutes comprising the
United States patent system. Section V takes up the question of
whether gene fragments are patentable under the current statutory
framework. Section VI addresses some of the public policy issues
raised by attempts to patent genes. Section VII examines various judi-
cial and legislative approaches that have been suggested to remove the
patent system as an obstacle to continued progress in biomedical
research.
II. ScINTIFIc BACKGROUND
Dr. Francis Collins, head of the National Center for Human Gen-
ome Research at the NIH, recently stated, "Biologists do not under-
stand patent law and patent lawyers do not understand biology."'" In
order to understand the controversy that has been generated by the
NIH's attempt to patent gene fragments, it is necessary to possess a
minimum level of knowledge about the field of biotechnology and the
science of genetics. The following section provides background infor-
mation on the explosive progress that has been attained in the biotech-
nology field in recent years.
9. Rick Weiss, NIH Abandons bid to Patent DNA Fragments, WASH. POST, Feb. 11,
1994, at Al.
10. Wuethrich, supra note 7, at 159. See also Human Genome Plots Over 45,000 Genes in
Smith-Kline Pact, W. ST. JoUt., Apr. 8, 1994, at C17 (reporting that Smith-Kline Beecham
provided Human Genome Sciences, Inc. with $12.5 million in additional funds after Human
Genome Sciences sequenced more than 45,000 genes).
11. Ruth SoRelle, World Forum Spotlights DNA Mapping, Hous. CHRoN., Jan. 21, 1994,
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A. Developments in Genetic Science
The science of genetics deals with how specific traits are passed
on from generation to generation. 12 In uncovering patterns of inheri-
tance, scientists have focused on the gene as the fundamental unit of
study. 3 Scientists believe that our genes play an enormous role in
shaping each of our lives. As Dr. James Watson, who, along with Dr.
Francis Crick discovered the structure of deoxyribonucleic acid
(DNA) in 1953, stated: "We used to think our fate was in our stars,
Now we know, in large measure, our fate is in our genes." 4 Genes
are found within the chromosomes of our bodies' cells. 5 A single set
of chromosomes-the haploid number-is present in the egg and
sperm cells of animals and also in the pollen cells of plants.' 6 All
body cells, or somatic cells, carry a double set, or diploid number, of
chromosomes. One set of chromosomes is inherited from each par-
ent. 7 Scientists define a genome as the set of all the genetic informa-
tion found in an organism's cells. 8 Before Watson and Crick's
discovery, scientists determined that genetic material: (1) has a struc-
ture that is maintained in stable form; (2) is able to replicate itself; (3)
has an information code that is expressed;' 9 and (4) is capable of
change or variation.20 Based on these discoveries, scientists came
closer to understanding how specific traits are passed along. For ex-
ample, scientists in 1911 located the gene for color-blindness on the
human X chromosome.' With the 1953 discovery, however, scien-
tists were able to view the structure of the carrier of genetic informa-
tion itself-the DNA molecule. An understanding of the structure of
DNA is vital to understanding how genes determine our specific
traits.2
2
12. James D. Watson, et al., MoLEcuLAR BiotooY oF "m GEN, ch. 1 (4th ed. 1987).
13. MAPPING Oup GENwS, supra note 1, at 43 (describing the development of the history of
genetic science).
14. Leon Jaroff, The Gene Hunt, Tnem, March 20, 1989, at 67.
15. MAPPiNG Ou GrarEs, supra note 1, at 21.
16. Id
17. Id.
18. Id.
19. The term "expression" refers to the process of converting DNA into protein molecules.
id, at 21.
20. Id.
21. Id.
22. See James D. Watson & Francis Crick, Molecular Structure of Nucleic Acids, 171
NATuRE 737-738 (1953) (describing the structure of DNA). See also TROY DusrR, BACKDoOR
-to EuGEmcs 18-34 (1990) (providing the arguments for and against the deterministic view that
our genes determine who we are).
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Chromosomal DNA is found within each of our bodies' aproxi-
mately 100 trillion cells.' Cells are the "building blocks of life...
[they are] sophisticated chemical factories with the ability to grow and
divide to produce progeny cells, which also generate new cellular mol-
ecules and replicate themselves."'24 There are two types of cells:
eukaryotic cells, which have a "membrane-bound, spherical body
called the nucleus," and prokaryotic cells, which do not have nuclei.2'
Except for red blood cells, each human cell contains a nucleus.26
With the exception of the egg and sperm cells, each cell's nu-
cleus contains a diploid number of forty-six chromosomes, arranged in
twenty-three pairs.2 The chromosomes are made up of tightly coiled
strands of DNA. 28 Watson and Crick discovered that the DNA mole-
cule in multi-cellular animals consists of two linear strands wrapped
around each other in the form of a double helix.29 Each strand is a
polymeric chain made of nucleotides, which consist of sugars,
phosphate groups, and bases.3"
There are two kinds of bases: purines and pyrimidines. The two
purine bases are adenine ("A") and guanine (G"); the three pyrimi-
dines are cytosine ("C"), uracil ("U"), and thymine ('T').3 ' Uracil is
found only in ribonucleic acid (RNA), while thymine is found only in
DNA. 2 When nucleotides are linked together in large numbers, a
polynucleotide is formed. 3 Each strand of DNA, therefore, is com-
posed of three parts: a sugar, a phosphate group, and a base. The
sugar and phosphate group form the "backbone" of the strand, while
the phosphate group serves to link one sugar-base molecule to an-
other.34 The two backbones wind around each other in spirals creating
23. Phillip Elmer-DeWitt, The Genetic Revolution, Tuai, Jan. 17, 1994, at 50 (providing a
useful chart on the location of cells, nuclei, chromosomes, DNA and genes within the human
body).
24. Richard J. Smith, Basic Principles of Genetic Engineering at 1 (unpublished article,
copy on file with author).
25. Id. at 2.
26. Elmer-DeWitt, supra note 23, at 50.
27. Id. Each parent contributes one chromosome of each pair. Id.
28. 1&.
29. MAPPiNG Ott GENEs, supra note 1, at 21.
30. Id.
31. See Smith, supra note 24, at 3. See also EvE K. NicHoLs, HumAN G NE THEAPY 24
(1988) (describing how scientists with the NIH, NYU, and the University of Wisconsin in 1961
identified the four nitrogen bases found in DNA).
32. Smith, supra note 24, at 3.
33. MAPPING OuR G arEs, supra note 1, at 23.
34. I& at 22.
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a double helix. 5 The bases are perpendicular to the sugars and stack
up on one another, much like steps in a spiral staircase.36
The basic message found in DNA-the "genetic code"-consists
of a sequence of bases notated by the letters A, C, G, and T.37 RNA
contains the same sequences of letters, except that uracil (U), rather
than thymine (M), is found in RNA. The bases are complementary: A
pairs with T (or with U in RNA), and C pairs with G. The genetic
code is read in series of three letters (e.g., CCG) during the conversion
of DNA into protein molecules (referred to as "gene expression").38
A gene is a "region of a chromosome whose DNA sequence can be
transcribed to produce a biologically active RNA molecule."39
The first step in the expression process is transcription, 40 during
which an RNA polymerase4l binds to the DNA at the correct starting
point and then moves down the DNA chain adding the proper nucleo-
tides to the RNA chain until the task is completed.42 Throughout the
transcription process, certain nucleotides in the chain are modified and
others are excerpted by a splicing mechanism, finally yielding a chain
of polynucleotides that is shorter than the primary DNA chain
transcribed.4 3
The next step in the expression process is translation, during
which a messenger RNA (mRNA) molecule delivers instructions for
encoding a protein to a ribosome.4 Transfer RNAs (tRNAs) then
transfer amino acids to the ribosome synthesis site.4" The tRNAs
carry anti-codons, which complement the codons carried by the
mRNA.46 The ribosome has two binding sites: one for positioning the
arriving tRNAs and the other for holding the growing polypeptide
chain composed of amino acids.47 The tRNAs bring the selected
35. Id.
36. Id.
37. Id.
38. 1U.
39. Id. at 24.
40. Id. at 23. See also id. at 24 (describing how DNA can also be reproduced through the
process of replication. In replication, the DNA molecule separates into two strands. Each strand
then forms a new DNA molecule by combining with free nucleotides in the nucleus. The
"daughter" molecules formed in the replication process are identical to the original DNA
molecule).
41. A polymerase is an enzyme that consists of large multi-subunit proteins. It is responsi-
ble for catalyzing the transcription process. For a detailed discussion of the role of polymerases
in the regulation of genes, see Norman MacLean, Gms mAD GEm RzEaUTIoN 74-77 (1989).
42. MAPPING OuR GEms, supra note 1, at 23.
43. Id. at 23-24.
44. Smith, supra note 24, at 4-5.
45. Id at 5.
46. MAPPi'Nc OuR GENES, supra note 1, at 23.
47. Id
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amino acids to the synthesis site where they are joined to the polypep-
tide chain. The ribosome will stop the process when it reads a halt
signal in the mRNA.4 8 At this point, the translation process is com-
plete: the polypeptide chain represents a protein. Gene expression is
vitally important, because proteins form the "basis. of all living phe-
nomena as structural support, catalyst of equisite activity, storage me-
dia, transport systems, hormone messengers, etc."'4 9
Scientists estimate that there are between 50,000 and 100,000
genes per human haploid genome (i.e., per twenty-three chromo-.
somes).50 Each gene may comprise as few as 10,000 or as many as 2
million base pairs,"1 and it is important to note that most of the DNA
sequences that make up the human genome are not expressed. "Every
cell of the human body has the complete set of human genes. But
each type of cell expresses only a handful of the total-those it needs
to perform its biological role" of creating proteins. 2 Scientists have
divided genes into coding regions comprising exons and non-coding
regions comprising introns. Only exons are translated into proteins;
the introns are removed by a splicing mechanism. 53 Currently, scien-
tists "do not know what to make of introns...,.
Based on an improving knowledge of molecular biology, scien-
tists in the 1960s developed rudimentary techniques for locating
human genes within chromosomes.5 5 At that time the science of ge-
netics was based on the analysis of inheritable diseases and other eas-
ily observable traits that could be linked to family trees.56 In the late
1960s and the 1970s, scientists began to develop maps of human
genes based on direct observation of chromosomes. 57 In the late
1970s and early 1980s, scientists began to use biochemical analysis to
map genes s. At that time, scientists focused on DNA fragments of
known location but unknown function in order to study the inheritance
of certain traits. These fragments served as "markers" to link the frag-
48. Robert P. Ouellette & Paul N. Cheremisinoff, EssmaMA.S OF BiOTECHNOLOGY 8
(1985). See also Smith, supra note 24, at 5 (noting that three combinations of bases (UAA,
UAG, and UGA) code for stop signals).
49. Ouellette & Cheremisinoff, supra note 48, at 9.
50. This number appears to be based on the results of chromosome, banding research.
Scientists have identified 1,000 distinct bands on the 24 human chromosomes and an average of
100 chromosomes is represented in a single band. MAPPiNG OuR GqENs, supra note 1, at 33.
51. Id. at 24.
52. Wuethrich, supra note 7, at 159.
53. Ouellette & Cheremisinoff, supra note 48, at 21-22.
54. Id.
55. MAPPING OuR GENzms, supra note 1, at 4.
56. Id.
57. Id.
58. 1&. at 6.
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ments to specific chromosomes. 9 By using these techniques, scien-
fists could determine which DNA fragment came from which parent.
Scientists could use the markers to identify the location of genes dis-
covered in close proximity to a marker because the gene and the
marker would be inherited together.' Scientists began to construct
maps of DNA markers in the early 1980s. 11
B. The Rise of the Biotechnology Industry
The explosion in biotechnology research followed the advances
in the field of molecular biology. Biotechnology is a broad field that
encompasses
any process in which organisms, tissues, cells, organelles, or iso-
lated enzymes are used to convert biological or other raw materials
to products of greater values, as well as the design and use of reac-
tors, fermenters, downstream processing, analytical and control
equipment associated with biological manufacturing processes.62
Stanley N. Cohen and Herbert W. Boyer were the first research-
ers to remove a gene from the genome of a donor organism and suc-
cessfully recombine that gene with the DNA of a host organism by
introducing cells containing the gene into the host organism. 63 Cohen
and Boyer received three patents on "biologically functional molecu-
lar chimeras" for their efforts, launching the biotechnology industry.64
Genentech, the first firm in the world to exploit recombinant DNA
(rDNA)65 technology, was founded in San Francisco in 1976.66 In
1982 Richard Palmiter and Ralph Brinster injected human growth hor-
mones into mice, creating the first transgenic animals.6 7 In 1985 Kary
Mullis pioneered the polymerase chain reaction (PCR), which enabled
scientists to clone huge quantities of any fragment of a gene and in
some cases construct the complete gene from the fragment. 68
59. Id.
60. Id.
61. Id.
62. J. Coombs, DIcIoNARY OF BIoTEcHNoLooy 45 (1989).
63. Pamela A. Docherty, The Human Genome: A Patenting Dilemma, 26 AKRON L. Rv.
525, 574 n.120 (1993).
64. See id. (citing U.S. Patent Nos. 4,237,224, 4,468,464, and 4,740,470).
65. See OFFICE OF TEcHNOLooy AssEssMENT, U.S. CONoREss, BIOTECHNOWY IN A
GLOBAL EcoNoMY 3-10 (1991) (describing the history of rDNA technology and some current
applications).
66. Jaroff, supra note 14, at 56.
67. Mark Fischetti, The Blossoming of Biotechnology: Harvesting Miracle Drugs, Better
Plants, and Lots of Confusion, Om, November 1992, at 68.
68. Id. The PCR technique is defined as a "technique for amplifying a short stretch of
DNA. The method depends on the use of two flanking oligonucleotide DNA primers and re-
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With the discovery of the PCR technique, scientists realized that
it would be possible to find genes based on partial gene sequences;
and in 1984 and 1985 Robert Sinsheimer, Renato Dulbecco, and
Charles DeLisi proposed the idea of sequencing the entire human
genome.69
C. Developments in Genome Research
In 1985, the DOE began planning its Human Genome Initiative
(HGI) by .holding several public meetings aimed at developing a
framework for promoting research in molecular biology.70 The HGI
officially began in late 1986, focusing on two projects: (1) creating an
ordered set of DNA segments from known chromosomal locations;
and (2) developing new computational methods for analyzing genetic
map and DNA sequence data. 1 Following the efforts of the DOE, the
NIH began to promote genome research in 1987.72
Since 1987, NIH researchers have focused on two areas: (1) im-
proving the methods of analyzing the human genome and the genomes
of other complex organisms; and (2) enhancing computational meth-
ods of analysis.73 The Howard Hughes Medical Institute (HHMI) and
the National Science Foundation (NSF) have also spent millions (per-
haps billions) of dollars researching the human genome.74
Human genome research has not been confined to United States
government laboratories. In 1988 and 1989 the federal government
spent almost $70 million on genome research.75 By October 1990, the
NIH set aside a budget of $87.5 million for genome research and the
DOE set aside $46 million.76 "[M]apping genes has been an interna-
tional effort since its inception. International agreements for databases
(particularly those containing DNA sequence data) and collaborations
on gene mapping (notably the Center for the Study of Human Poly-
morphism in Paris) have been in operation for several years. 77 At the
same time that the United States government began to fund genome
peated cycles of extension using the enzyme DNA polymerase." GENE MAPPING: USING LAW
AND Ermcs As GuIDas 279 (George J. Annas & Sherman Elias eds., 1992).
69. Robert Mullan Cook-Deegan, The Genesis of the Human Genome Project, 1 Mot.acu-
AR GEmrtc MDIcNm 1 (1991).
70. MAPPINo OUR GmE.s, supra note 1, at 46.
71. I4
72. Icd
73. lit at 8.
74. Id
75. Rebecca S. Eisenberg, Patenting the Human Genome, 39 EmoRY Li. 721, 738 n.66
(1990).
76. Id
77. MAPPING OUR GENEs, supra note 1, at 46.
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research efforts, several special genome projects were already under-
way in Italy, the United Kingdom, the Soviet Union, Japan, France,
and the European Communities.7 8 While no foreign government has
yet committed itself to mapping the entire human genome, researchers
in the United Kingdom have successfully mapped the genome of a
non-human organism, while scientists in Italy have attempted to map
the genes contained in a single chromosome.79 Following these ef-
forts, a new international organization, the Human Genome Organiza-
tion (HUGO) was formed-in 1988,3°
The intense study of the human genome has produced remarkable
results. According to Dr. Victor McCusick, of Johns Hopkins Medical
School, the location of only 606 genes was known in 1983;1 however,
since that time,, due to the efforts of researchers around the world,
thousands of genes have been "discovered." 2 By March of 1993, ac-
cording to McCusick, over 2,600 genes had been fully mapped. 3
However, technology to automate parts of the research process, devel-
oped in the last two years, has dramatically increased the rate at which
genes are being located. According to Dr. Michael Haseltine, Chair-
man of Human Genome Sciences, Inc., located in Maryland, "We're
finding 300 to 400 new genes per day."' '
III. THE NIH's ATrEM]PT TO PATENT.GENOME RESEARCH
A. Dr. Venter's Discoveries
Dr. J. Craig Venter, former chief of receptor biochemistry at the
National Institute of Neurological Disorders and Stroke of the NIH,
discovered a ,short-cut for identifying fragments of genes in 1990.85
Dr. Venter had been frustrated by the lack of progress in identifying
genes along a 100,000 base-pair stretch of chromosome 19.86 "We
found that even when we had big sequences of human chromosomes,
on the order of 100,000 base pairs of DNA, the sequence was, for all
78. McLAPEN, HumAN GEiomE REsEARCH: A REVIEW OF EUROPEAN AND INTERNA.
'noNAL CorRamurnoNs 14 (1991).
79. MAPPING OUR GENEs, supra note 1, at 8.
80. Id.
81. Michael Waldholz, Huntington's Disease Gene is Found at Last, WAu. ST. J., March
24, 1993, at BI.
82. Id.
83. Id.
84. Jerry E. Bishop, Human Genome Sciences Sees Gold in Trove of Genes, WAL. ST. J.,
March 18, 1994, at B4.
85. Gina Kolata, Biologist's Speedy Gene Method Scares Peers But Gains Backer, NY
Tmirs, July 28, 1992, at CIO, col. 2.
86. Id.
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practical purposes, uninterpretable."' 7 The reason the sequence was
"uninterpretable" is because of the amount of "useless information" in
the human genome: "The 100,000 genes in human cells account for
only a small fraction of the DNA in the genome. Most of the rest, as
far as scientists can tell right now, is just molecular garbage.""8 Fur-
thermore, as previously discussed, most of the sequences found in
genes are not expressed, i.e., they do not encode a protein. An article
in Science News recently stated that "A gene can include hundreds of
thousands of bases. However, the vast majority of these, serve no
known purpose. Perhaps only 2 to 5 percent of all bases are 'ex-
pressed' ..."I'
Dr. Venter realized that researchers could theoretically speed up
the process of identifying genes by focusing on mRNA molecules,
reasoning that, because the mRNA picks up the blueprint of an ex-
pressed gene during the transcription process, it should be possible to
obtain a copy of that blueprint by transcribing mRNA molecules back
into DNA. A recent article describes the technique as "fishing
mRNA's out of cells and examining them [in order to] deduce the
sequences of genes."90 The DNA produced as a result of this process
is called complementary DNA or cDNA.
91
After obtaining the cDNA strands, Dr. Venter sequenced small
stretches of the material by "using robots and computers to do jobs
that are often done laboriously by hand in molecular-biology laborato-
ries."92 The computers found gene "fragments, some only eighteen
bases long ... called expressed sequence tags (ESTs) because they
can be used to track down the complete gene."93 The NIH's com-
puters would then attempt to match up the ESTs with "[k]nown genes,
from yeast to humans, looking for ones that resembled the fraghents
he sequenced."94 Using. Dr. Venter's technique, researchers were
finding genes at the rate of 2,000 a month at the time he left the
N.I.H.95 Furthermore, Dr. Venter expected the rate of discovery to
increase, stating that he expected to find approximately 10,000 frag-
87. Id.
88. Fish Gene May Provide Shortcut in DNA Project, SAN ANromo ExpPmss-Naws, Jan.
17, 1994, at 2E.
89. Wuethrich, supra note 7, at 155.
90. Kolata, supra note 85, at CIO.
91. Id
92. Kolata, supra note 85, at CIO, col. 3.
93. Wuethrieh, supra note 7, at 155.
94. IL
95. Kolata, supra note 85, at C2.
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ments a month, armed with an $80 million grant from his new em-
ployer, the Institute of Genomic Research. 6
After Dr. Venter used this process to "discover" 347 cDNA frag-
ments, he decided to publish his work; however, an NIH attorney
warned him that publishing might create a disincentive for companies
to use the research to develop new drugs.9 7 The attorney reasoned that
a company might locate the entire gene, based on Dr. Venter's identi-
fication of a gene fragment, and be unable to patent the discovery
because Dr. Venter's research was in the public domain.98 Dr. Venter
ultimately decided not to publish his results until the NIH filed patent
applications on the gene fragments. "I thought it was just irresponsi-
ble to just dump all this stuff and make it so that the biotech industry
and the pharmaceutical industry could not get patent protection." 99
The NIH filed its patent application on the 315 cDNA fragments
sequenced by Dr. Venter in June 20, 1991, and filed a continuation-in-
part application covering approximately 2,400 additional fragments in
February 1992.1° The PTO rejected both applications in August
1992, and the NIH then filed another continuation-in-part application
on 4,448 cDNA fragments in September 1992 and also appealed the
PTO's August 1992 finding. 10 1 In reviewing the applications, the
PTO once again rejected the earlier claims and also rejected the new
claim, giving the NIH until midnight on February 10, 1994 to appeal
the decision. Dr. Bernadine Healy, the Director of the NIH at the time
of the patent controversy, commented that the PTO rejected the patent
applications because
[t]he gene fragments weren't novel because they were derived from
publicly available libraries of gene sequences ... It also said the
fragments didn't have a practical use, or patentable utility. And it
said the discoveries failed to meet the criteria of 'nonobviousness'
because some of the gene sequences contained smaller sequences
that were already published.102
The NIH decided not to appeal the PTO's decision and aban-
doned its patent applications in February 1994.103 The controversy
96. Id
97. Id
98. Id
99. Id.
100. Docherty, supra note 63, at 525.
101. Id
102. Hilary Stout, Gene.Fragment Patent Request Is Turned Down, WALL ST. J., Sept. 23,
1992, at B1.
103. Rick Weiss, NIH Abandons Bid to Patent DNA Fragments, WASH. Post., Feb. 11,
1994, at Al.
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generated by the NIH's attempts to patent gene fragments created
shockwaves in the scientific community both here and abroad.
B. The Reaction to the NIH's Applications
Dr. Watson resigned as head of the NIH's Center for Human
Genome Research amidst the controversy generated by the govern-
ment's attempt to patent gene fragments. Dr. Watson castigated the
NIH for pursuing a policy based on "sheer lunacy,"" 4 arguing that
"seeking ownership over unknown genes would undermine efforts to
get governments, universities and companies to work together to seek
disease-causing genes.""0 That the new director of the NIH, Dr. Har-
old Varmus, was acutely aware of the patent controversy is obvious
from the following statement made shortly after joining the agency: "I
do not believe that patenting at this stage promotes technology devel-
opment, and it may impede more important research collaborations
here and internationally."'0 6 Furthermore, Dr. Francis Collins, the
new director of NIH's National Center for Human Genome Research,
now agrees with Dr. Wation that "ESTs without known function are
not and never should be patented."' 0 7
The NIH's refusal to appeal the PTO's decision does not mean
the issue of whether gene fragments are patentable is dead. Private
sector companies are now stepping up their research efforts in this
area and plan to file patent applications on gene fragments and many
researchers "are worried that if they don't patent these discoveries,
someone else will."'0 8 The NIH's initial decision to patent gene frag-
ments now threaten to create an "avalanche of patent applications by
industry."'" The PTO's decision also creates uncertainity in the bio-
technology industry, as Dr. Francis Collins notes: "[the PTO's deci-
sion] doesn't resolve the question of what it takes to win a patent, [but
the decision may] improve the scientific atmosphere."" 0 According
to Dr. Collins, the NIH's decision to abandon its applications merely
postpones the resolution of the "vexing questions related to the patent-
ing of genes."'' This comment leaps into the fray and takes up some
of these vexing questions in the following sections; however, before
104. ld.
105. Michael Waldholz, NIH Gives Up Effort to Patent Pieces of Genes, WALL ST. J., Feb.
11, 1994, at BI.
106. IL
107. Wuethrich, supra note 7, at 158.
108. Waldholz, supra note 105, at BI.
109. UL
110. Id.
Ill. Id&
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evaluating whether patents should issue on gene fragments, it is neces-
sary to briefly describe the goals of the United States patent system.
IV. THE UNITED STATES PATENT SYSTEM: OBJECTIVES AND
STATUTORY REQUIREMENTS
In order to understand why the PTO rejected the NIH's patent
applications, it is necessary to review the patent law system that exists
in the United States.
A. Purpose
The United States system of patent law has a constitutional and a
statutory basis. Article I, Section 8, clause 8 of the Constitution em-
powers Congress to "[piromote the Progress of Science and useful
Arts, by securing for limited Times to Authors and Inventors the ex-
clusive Right to their respective Writings and Discoveries."" 2 One
commentator argues that "[b]ased on studies of colonial syntax and
usage, the clause should be read disjunctively as: (1) 'The progress of
science is to be promoted by securing to authors the right to their
writings; and (2) the progress of the useful arts is to be promoted by
securing to inventors the right to their discoveries.' "113 Since the
constitutional authorization does not specify the length of time that the
invention will be protected or the scope of protection, Congress was
left the discretion to act, under its Article I authority, in a manner
consistent with the framers' intent.
Congress first enacted a patent system in 1790,114 but the system
has been overhauled several times since then, most recently in
1952." 5 Despite the statutory changes, the constitutional objective of
system has remain unchanged since 1790. As the Supreme Court has
recognized, the "[n]Iltimate goal of the patent system is to bring new
... technologies into the public domain through disclosure."116 Fur-
thermore, the Court has held
The authority of Congress is exercised in the hope that "the produc-
tive effort thereby fostered will have a positive effect on society
through the introduction of new products and processes of manu-
112. U.S. CONST. art. 1, § 8, cl. 8.
113. Michael S. Greenfield, Recombinant DNA Technology: A Science Struggling with the
Patent Law, 44 STAN. L. REv. 1051, 1056 (1992).
114. An Act to Promote the Progress of Useful Arts, ch. 7, 1 Stat. 109 (1790) (repealed
1793).
115. Patent Act of 1952, PuB. L. No. 82-593, 66 Stat. 792 (codified as amended at 35
U.S.C. §§ 1-376 (1988)).
116. Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 151 (1989).
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facture into the economy, and the emanations by way of increased
employment and better lives for our citizens."
' 17
B. Statutory Requirements
Pursuant to its Article I authority, Congress has enacted several
statutory provisions dealing with patents. Biotechnology discoveries
currently fall under the same set of statutes as any other discoveries.
In order to receive a patent, the patentee must demonstrate that (1) the
invention falls within the broad category of patentable subject matter,
(2) is novel, (3) is non-obvious, (4) has utility, and (5) is adequately
disclosed." 8
If these statutory requirements are met, the holder of a United
States patent possesses the exclusive right to make, use, or sell the
patented invention in the United States for a period of seventeen years
from the date the patent issues.'1 9 The patentee may exclude anyone
from using the invention for any purpose during this time period. For
example, the patentee may prevent an innocent infringer who- develops
the same invention independently from using the invention."20 Fur-
thermore, a subsequent inventor who improves on the existing inven-
tion will generally also be liable for patent infringement. In order to
earn the rights conveyed by a patent, the patentee must disclose the
invention to the world such that those who are "skilled in the art" are
able to make and use the invention. 2' The disclosure requirement is
the quid pro quo of gaining the patent monopoly. 22 The patent itself
describes the invention and of how to make and use it. The descrip-
tion is accompanied by figures or drawings and one or more claims
specifying exactly what others may not freely make, use or sell. 1
In summary, in order to Obtain a 'patent, an applicant must
demonstrate that the discovery meets the patentable subject matter test
117. Diamond v. Chakrabarty, 447 U.S. 303, 307 (1979) (quoting Kewanee Oil. Co. v. Bi-
cron Corp., 416 U.S. 470, 480 (1974)).
118. These requirements are found at 35 U.S.C. §§ 101 (patentable subject matter require-
ment, novelty requirement, and utility requirement), 102 (novelty requirement); 103 (non-obvi-
ousness requirement), and 112 (disclosure requirement). See also Michael A. Epstein, MODERN
I tr.NruAL. PRioPaTY 434 (1992) ('In order to be patentable, biotechnology inventions must
meet the statutory requirements... These requirements are that the invention fall within one of
the statutory classes of patentable subject matter, and be novel, non-obvious, useful and ade-
quately disclosed.").
119. 35 U.S.C. § 154. See also Rebecca S. Eisenberg, Patent Rights in the Human Genome
Project, in GENE MAPING 227 (1992) [hereinafter Hwnan Genome Project] (discussing the
scope of the patent).
120. Id.
121. 35 U.S.C. § 103. See also Human Genome Project, supra note 119, at 227.
122. Id.
123. 35 U.S.C. 99 112-113.
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and is novel, non-obvious, useful, and adequately disclosed. The fol-
lowing section applies each of these criteria to cDNA sequences.
V. ARE GENE FRAGMENTS PATENTABLE UNDER THE CuRmRNT
PATENT SYSTEM?
A. Section 101: Patentable Subject Matter
Section 101 of the Patent Act broadly defines patentable subject
matter as "any new and useful process, machine, manufacture, or com-
position of matter, or any new and useful improvement
thereof.... ." Case law confirms that the products and processes
discovered through biotechnology research may be patented. This is
significant, as Epstein notes, because "[t]he biotechnology industry is
a growing and very active one, with intellectual property protection
very important for this growth.... The ability of companies to obtain
protection for inventions in these and other areas can provide them
with a significant competitive advantage.""a  Recently, Lisa Raines,
of the Industrial Biotechnology Association, described patents as "the
lifeblood of the biotech industry."12 6
While the "products of nature" doctrine-which holds that prod-
ucts of nature, as such, cannot be patented-once stood as an obstacle
to biotechnology patents, that doctrine has been steadily eroded by
Congress, the PTO, and the courts. 2 7 Congress has approved the pat-
124. 35 U.S.C. § 101.
125. EpsrrN, supra note 118, at 433.
126. Michael Waldholz & Hilary Stout, A New Debate Rages Over the Patenting of Gene
Discoveries, WAuL ST. J., April 17, 1992, at B1.
127. The doctrine originated in a 1948 U.S. Supreme Court decision, Funk Brothers Seed
Co. v. Kalo Innoculant Co., 33 U.S. 127 (1948). Justice Douglas, writing for the majority, held
that
patents cannot issue for the discovery of the phenomena of nature... The quali-
ties of these bacteria, like the heat of the sun, electricity, or the qualities of metals,
are part of the storehouse of knowledge of all men. They are manifestations of
laws of nature, free to all men and reserved exclusively to none.
Ia at 130. Turning to the facts at issue, Justice Douglas held that the patentee created no new
bacteria and that the bacteria in the mixed culture continued to "serve the ends nature originally
provided and act quite independently of any efforts of the patentee." Id. Under Justice Doug-
las's line of reasoning, today's biotechnology products-which are valuable precisely because
they "serve the ends nature originally provided"-would arguably not be entitled to patent pro-
tection. Fortunately for the industry, the Court moved away from Funk Brothers in later deci-
sions, most notably Diamond v. Chakrabarty, 447 U.S. 303 (1980). Chakrabarty held that
"anything under the sun made by man" may be patented. IaL at 309 (quoting S. Rm'. No. 1979,
82d Cong., 2d Sess. 5 (1952) and H.R. Rm. No. 1923, 82d Cong., 2d Sess. 6 (1952)). In
Chakrabarty the Court recognized that certain biotechnology products are entitled to patent pro-
tection. The patentee sought protection for organisms that had been altered by the introduction
of multiple naturally occurring plasmids to allow them to break down crude oil. The patent
examiner rejected the application on the alternative grounds that (1) the micro-organisms were
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enting of plants as life forms under the Plant Patent Act (PPA) of 1930
and the Plant Variety Protection Act (PVPA) of 1970. However, case
law has extended patent protection to other genetically engineered or
modified life forms.' 28 For example, in 1980, the Supreme Court
ruled that man-made life forms are patentable, in Diamond v.
Chakrabarty.2 9 The Court specifically held that Congress, when it
enacted the 1952 Patent Act, intended to protect under the patent laws
"anything under the sun that is made by man."' 3 °
In 1985 the PTO Board of Patent Appeals, in the case of Ex
parte Hibberd,131 held that section 101 allows patents on plants, seeds
and plant tissue cultures.'32 While the PPA and PVPA did not author-
ize patents on the applicants' tissue cultures, the Board ruled that sec-
tion 101 covered the subject matter.'33 The Board had the opportunity
to limit the scope of section 101 in 1987 when an examiner rejected
patents on polyploid oysters on the ground that "living entities" could
not be patented under section 101.' 34 However, in reversing the ex-
aminer, the Board held that the claimed oysters owed their existence
to the intervention of man, i.e., these oysters would not exist in na-
ture.' 35  Following the courts' decisions, the PTO announced that it
would issue patents covering non-human multicellular animals. 136
"products of nature;" and (2) that living organisms could not be patented in any case. The PTO
affirmed the examiner on the second ground, while rejecting the first ground due to the fact that
these organisms did not occur in nature.
In addressing the issue of whether the altered organisms were patentable, the Court held the
inventor was entitled to patent protection because he created "a new bacterium with markedly
different characteristics from any found in nature ... [the organism represented] not nature's
handiwork, but his own; accordingly it is patentable subject matter .... Chakrabary at 310.
See also Eisenberg, supra note 75, at 726 ("Under Chakrabarty, the relevant inquiry for distin-
guishing between patentable subject matter and unpatentable products of nature is whether the
claimed invention is the result of human intervention"). Following the Court's willingness to
protect products of biotechnology research, the PTO in 1987 extended patent protection to "non-
naturally occurring non-human multicellular living organisms, including animals." Id. at 725
(citing Non-naturally Occurring Non-Human Animals are Patentable under Section 101, 33 PAT.
TRADMAnK & COPYRIGHr J. (BNA) No. 927, at 664 (Apr. 23, 1987)).
128. See, e.g., In re Bergy, 596 F.2d 952, cert. granted, 444 U.S. 924 (1979), vacated, 444
U.S. 1028 (1980) (holding that live man-made organisms may be patented under 35 U.S.C.
§ 101). See also EpsmN, supra note 118, at 435 (discussing additional cases expanding the
scope of patentable subject matter to include products of biotechnology research).
129. 447 U.S. 303 (1980).
130. Id. at 309.
131. 227 U.S.P.Q. 443 (1985).
132. Id. at 443.
133. Id. at 447.
134. Ex parte Allen, 2 U.S.P.Q.2d 1425 (1987).
135. Id. at 1426-27.
136. Epstein, supra note 118, at 437.
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Given the broad reading of section 101 applied by the courts and
the PTO, it is not surprising that several important patents covering
DNA sequences were issued in the 1980s.'3 7 For example, patents
have issued'38 on a DNA sequence encoding a plasminogen activator
protein,"3 9 a DNA sequence for erythropoietin, 11 a DNA sequence for
a human T-cell antigen receptor,' 4 ' and a DNA sequence for human
factor VIII: C.'42 Given these patents, today it seems clear that the
gene. fragments at issue here are arguably within the range of patenta-
ble subject matter covered by section 101.
B. Section 102: Novelty
It is a fundamental axiom of patent law that one cannot obtain a
patent on something that is not new. While, section 101 requires that
the subject matter covered by the patent be "new and useful,"'143 the
condition of newness or novelty is defined in section 102 and requires
that the invention must not already be available to others by any
kind of public disclosure or use before the date of filing of the
patent application. Although the rule is commonly expressed in
terms of 'publication' it is important to note that this includes all
forms of public disclosure and use prior to the patent application,
even those made by or due to the inventor himself.14
The United States, Canada, Japan and a few other countries allow
an inventor to gain a patent even if the inventor publishes the discov-
ery prior to filing a patent application. However, a patent application
must be filed within one year of the date of publication. 4-
As previously discussed,' 46 the NIH filed its firt patent applica-
tion on June 21, 1991, and Dr. Venter published the results of his
research in Nature on the same date. 47 Therefore, since the patent
application was presumably filed before Dr. Venter's research was
137. Eisenberg, supra note 75, at 721 n.4.
138. See id.
139. U.S. Patent No. 4,370,417, Hung, et al., inventors, 1026 Off. Gaz. Pat. Off. 1315 (Jan.
25, 1983).
140. U.S. Patent No. 4,703,008, Lin, inventor, 1083 Off. Gaz. Pat. Off. 2038 (Oct. 27,
1987).
141. U.S. Patent No. 4,713,332, Mak, inventor, 1085 Off. Gaz. Pat. Off. 1386 (Dec. 15,
1987).
142. ' U.S. Patent No. 4,757,006, Toole, et al., inventors, 1092 Off. Gaz. Pat. Off. 878 (July
12, 1988).
143. 35 U.S.C. § 101.
144. R.S..Cpsp, PATENTS: A BAsIc GUIDE TO PAmErrnI IN BI0TCHNoLOGY 62 (1988).
145. Id.
146. See supra text accompanying note 100.
147. Kolata, supra note 85, at C2.
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published, the grace period discussed above would be irrelevant.
Thus, a patent could not be denied in any nation on the ground that the
NIH had disclosed the substance of the patent before filing a patent
application. 148
Although the "question of novelty has not been a major issue in
regard to the patentability and enforcement of patents on biotechnol-
ogy inventions-most likely because of the relative newness of most
of the technology involved,"149 the PTO denied the NIH's patent ap-
plications for the reason that the subject matter sought to be'patented
was not novel,150 finding that the "gene fragments weren't novel be-
cause they were derived from publicly available libraries of gene se-
quences ... ".151
Once Dr. Venter's research team synthesized the cDNA strands,
the fragments were placed in the public domain.' 52  Because the
NIH's automated robots hereafter did nothing more than sequence
publicly available gene fragments, the PTO's ruling is not surprising.
If the cDNAs had not been placed in the public domain, however, the
PTO may have reached a different conclusion.
Now that the NIH has abandoned its attempt to patent the cDNA
fragments identified by Dr. Venter, other companies will be forced to
litigate the question of whether their "discoveries" meet the novelty
standard. 153 As long as the fragments are not known or used by other
scientists prior to the date of identification and as long as the frag-
ments are not described in a publication more than one year before a
patent application is filed, then such companies will be able to reason-
ably argue that the novelty test should not prevent a patent from being
issued in the United States. However, if information about eDNA
molecules and gene fragments continues to reach the public domain, it
will become increasingly difficult to meet the novelty standard.
Therefore, less information on eDNA molecules and gene fragments
148. However, if Dr. Venter had published his research the day before filing the patent
application, then the patent would arguably have been denied in countries that do not provide
such a grace period.
149. EPsT N, supra note 118, at 440.1.
150. What the Patent Office Report Says, 258 ScmcEC 210, 211 (1992) (noting that the
PTO rejected the NIH's applications under §§ 101, 102(a), 103, and 112).
151. Stout, supra note 102, at 1.
152. After filing the patent application, the NIH placed the gene sequences into the
GenBank, a database available to the public. Paul H. Ginsberg, The NI- CDNA Patent Applica-
tion and Technology Transfer Issues, 7 J. oF PRoPRMTARY RiGHrs 18 (1992).
153. See also NIH Gene Patent Application is Debated at Forum on Human Genome, 44
BNA PAT., TRADEMARK & Coeymorr J. 73, 75 (1992) (statement of Richard Godown of the
Industrial Biotechnology Association) ("Many [biotechnology] companies fear that there may be
substantial litigation should should NIH or other parties obtain patents on partial gene
sequences.").
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will be released into the public domain if the current standard of nov-
elty remains unchanged. In section VII.C, this paper discusses how
the novelty requirement could be changed to promote biotechnology
research.
C. Section 103: Non-Obviousness
Section 103 of the Patent Act sets forth the requirement of non-
obviousness as follows:
A patent may not be obtained .... if the differences between the
subject matter sought to be patented and the prior art are such that
the subject matter as a whole would have been obvious at the time
the invention was made to a person having ordinary skill in the art
to which said subject matter pertains.'1 4
As public knowledge regarding biotechnology continues to ex-
pand, more biotechnology inventions will fail the current non-obvious
test. There is no different standard for biotechnology inventions, as
Epstein makes clear: "While the techniques and products of biotech-
nology may be unique and highly sophisticated, and the ordinary prac-
titioners in this area may have a very high level of skill, these
characteristics do not dictate a change in the legal standard, or its ap-
plication, to this field."' 55
The PTO ruled that the subject matter contained in the NIH's
patent applications was obvious in light of the existing prior art. Ac-
cording to Dr. Healy, the PTO rejected the NIH's applications because
the "discoveries failed to meet the criteria of 'non-obviousness' be-
cause some of the gene sequences contained smaller sequences that
were already published."a 56 The American Society of Human Genet-
ics (ASHG), a society of over 4,500 American and Canadian physi-
cians, scientists, and genetic counselors, also takes the position that
research on cDNA should not be patented because such research is
obvious:
An EST is simply a DNA sequence of a short segment of a cDNA
clone that is picked more or less at random from a set of cDNA
clones obtained by essentially standard published procedures. The
idea of picking a large number of cDNA clones and using the se-
quence of a short piece of each as a genetic marker or tag is an
obvious approach that has been extensively discussed in the human
154. 35 U.S.C. § 103.
155. Epstein, supra note 118, at 440.2.
156. Stout, supra note 102, at BI.
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genetics community and is currently the basis of on-going genome
projects both within and outside the USA. 15 7
If the ASHG is correct, then it may prove impossible to patent
any gene fragments (or even complete genes) in the future, as it is now
clear that using a reverse transcriptase enzyme to transcribe mRNA
molecules into cDNA molecules is an obvious process. It is also clear
that using computers and robots to obtain ESTs from the cDNA mole-
cules is obvious. Furthermore, it is now apparently obvious that ESTs
may be used to obtain a complete gene sequence-therefore, valuable
complete genes may be deemed unpatentable due to the fact that any-
one skilled in the art would have tried to discover the complete gene
based on ESTs.
Furthermore, once a full gene is found, it is obvious that the next
stage in the process is to identify the protein that it encodes-there-
fore, the protein itself may be unpatentable under section 103. The
possibility that the non-obvious requirement may act as a disincentive
to researchers raises the question of whether Congress should exempt
biotechnology discoveries from the scope of section 103. This com-
ment suggests that Congress study the feasibility of creating a special
intellectual property system for biotechnology research in part VII.C,
infra.
D. Section 101: Utility
Section 101 of the Patent Act provides than an invention or dis-
covery must be "useful" in order to be patentable.15 8 The utility stan-
dard is not often an issue in patent disputes because it would usually
be illogical to spend one's time trying to patent a useless invention.
As Epstein points out, "Utility is a de minimis standard, requiring
some showing that the invention has some practical use... This is a
relatively easy standard to meet in biotechnology inventions, which by
their nature have inherent biological activity." '159
R. S. Crespi, author of Patents: A Basic Guide to Patenting in
Biotechnology, explains the function of the utility requirement as
follows:
The U.S. patent law requires that an invention be useful and this
stems from the origin of the patent system as promoting "useful
arts." There are other useful arts than those of the industrial sphere
and the U.S. law is therefore most liberal in this respect. Utility
157. ARc c SOCmTY OF HUMAN GENEUcs, POSMON PAPER ON PATENTING OF Ex-
PREssED SEQuENcE TAGS 2 (1992) [hereinafter ASHG PosmoN PAPER].
158. 35 U.S.C. § 101.
159. Epstein, supra note 118, at 435.
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does have a practical connotation, however, as distinct from the
theoretical. A method of solving a math equation might not be pat-
entable insofar as it depended solely on a series of mental steps.
But a new method of filling a tooth would be patentable in the U.S.
even though it has nothing to do with industry.160
In 1966, the Supreme Court addressed the issue of utility in Bren-
ner v. Manson. 6' The Court rejected the applicant's claim to 2-
methyldihydroxytestosterone derivatives because the sole utility of
such substances "consist[ed] in their potential role as an object of use-
testing."' 62 The decision may have stemmed from the Court's fear
that granting the patents would "[c]onfer power to block off whole
areas of scientific development without compensating benefit to the
public."'16 According to the Court, "A patent is not a hunting license.
It is not a reward for the search, but compensation for its successful
conclusion."'" Furthermore, the Court held that a plaintiff must
demonstrate "substantial" utility representing a specific benefit in cur-
rently available form, because a "patent system must be related to the
world of commerce rather than to the realm of philosophy."' 65
Despite the holding in Brenner, Professor Rebecca Eisenberg, an
expert on the issue of patenting biotechnology-related products, pre-
dicted that the NIH patents would not be rejected for lack of utility.
According to Eisenberg,
Some critics of the NIH patent applications on partial cDNA se-
quences have argued that these inventions fail to satisfy this utility
requirement, but few patents are rejected on this basis. Patents
have been issued for DNA sequences that code for useful proteins
or that serve as probes to detect genetic susceptibility to disease. 166
The NIH claimed that the gene fragments were useful for various
purposes. Reid Adler, an attorney with the NIH, contends that the
fragments serve as "[m]arkers for chromosomes, and they are poten-
tially useful as polymerase chain reaction primers for amplifying and
cloning the genes."' 67 Professor Eisenberg adds that gene fragments
may be used "for forensic identification, or for tissue typing."' 68 Dr.
160. Crespi, supra note 144, at 71.
161. 383 U.S. 519 (1966).
162. lat at 531.
163. Id at 534.
164. Id at 536.
165. Id
166. Human Genome Project, supra note 119, at 228.
167. Leslie Roberts, NIH Gene Patents, Round Two, 255 SCIENCE 912 (1992).
168. Rebecca S. Eisenberg, Genes, Patents, and Product Development, 257 SciaEca 903
(1992).
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Venter asserts that "[t]hese are partial fragments [but] there is so much
information [in them]. There is more specific information than is in
your fingerprint for identifying you. ' 169 The NIH's patent applica-
tion, in addition to the above, justified patent protection on the
grounds that the fragments would help map locations of disease-asso-
ciated genes and would also be useful for preparing "triple helix
probes" that could be used to block the expression of a gene.170
Opponents of the patents, on the other hand, contend that gene
fragments lack utility. For-example, Thomas Kiley, an attorney and
director of various private and public biotechnology companies, as-
serts that the arguments for the utility of gene fragments are
pretextual:
To speak plainly, these are utilities concocted to carry the patents
until someone finds out what the DNA is really good for. Since-the
real purpose of the applications is to control individual DNAs and
thereby commerce in the proteins they encode, this approach, in my
opinion, amounts to a cynical resort to deficiencies in the law con-
cerning what utility is sufficient for patents.'
71
The ASHG asserts that ESTs are merely a "starting point for further
research [and therefore] should not be patentable."' 72 Despite Profes-
sor Eisenberg's warning that "[a] decision rejecting the NIH patent
claims for lack of utility would conflict with more recent lower court
decisions and would probably be unwise as a matter of public policy,"
the PTO ruled that the fragments lacked patentable utility.'73 The
PTO's decision may be unwise, as Professor Eisenberg contends, yet
the Board of Patent Appeals and Interferences has not ruled on the
issue of whether gene fragments are patentable. Furthermore, any ad-
verse Board ruling would likely be appealed to the Court of Appeals
for the Federal Circuit, and, if necessary, to the Supreme Court, for a
final resolution.
In the meantime, private companies plan to file patent applica-
tions on thousands of gene fragments in the near future. For example,
Roy A. Whitfield, the president of Incyte Pharmaceuticals, has stated
that the number of cDNA sequences found by NIH is "insignificant"
169. Hilary Stout, U.S. Pursuit of Gene Patents Riles Industry, WAIL ST. J., Feb. 13, 1992,
at B1.
170. Stephen B. Maebius, Novel DNA Sequences and the Utility Requirement: The Human
Genome Initiative, J. PAT. & TP.ADmAARK OFF. Soc'y, Sept. 1992, at 654 n.12.
171. Thomas Kiley, Patents on Random Complementary DNA Fragments?, 257 ScmNcE
915 (1992).
172. ASHG PosrroN PAER, supra note 157, at 3. But see Human Genome Project, supra
note 119, at 238 (asserting that when used for genetic screening tests these are end products).
173. Stout, supra note 169, at B1.
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compared to the number of sequences Incyte has discovered. In 1993,
Incyte was gearing up to sequence "as many as 100,000 cDNA se-
quences a year.... After accounting for redundancies, that means the
company will have sequenced the entire human cDNA library of
50,000 to 100,000 gene sequences by 1995... ."I74 Biotechnology
companies such as Incyte are fully aware of the utility requirement.
According to Whitfield, "in our patents we certainly address the ques-
tion of utility very strongly, and if we couldn't, then the new genes
probably wouldn't have much value."' 75
VI. PUBLIC POLICY IssUEs
Although the road towards receiving a patent may be costly, bio-
technology companies may be able to argue that, under current United
States patent law, patents may issue for discoveries of cDNA frag-
ments. The next question that arises is whether or not these fragments
should be patentable. This section presents and analyzes policy argu-
ments both for and against allowing patents on gene fragments.
A. Policy Background
Patent laws exist to promote socially useful research. Thomas
Jefferson, the author of the 1793 Patent Act, "like other Americans,
had an instinctive aversion to monopolies. It was a monopoly on tea
that sparked the Revolution and Jefferson certainly did not favor an
equivalent form of monopoly under the new government."' 76 In spite
of Jefferson's distrust of monopolies, he believed that the "social and
economic benefits from a patent system were so substantial that its
monopolistic characteristics should be suffered.""' Given the policy
basis of the patent system, it is important to discuss whether allowing
patents on cDNA fragments would further or hinder the policy objec-
tive of promoting socially beneficial research underlying the United
States patent system.
B. Policy Arguments in Support of the NIH
1. Patents Create Certainty
Dr. Bernadine Healy, former NIH Director, in a statement before
the Senate, justified the NIH's attempts to obtain patents as "a socially
174. Christopher Anderson, NIH to Appeal Patent Decision, 259 SCImEcE 301 (1993)(em-
phasis added).
175. Wuethrich, supra note 7, at 157.
176. Graham v. John Deere Co., 383 U.S. 1, 7 (1966).
177. Michael S. Greenfield, Recombinant DNA Technology: A Science Struggling with the
Patent Law, 44 STAN. L. Rnv. 1051, 1057 n.36 (1992).
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responsible way to ensure that products that are life-saving remedies
that can be derived from these [gene sequences] will be developed."' 78
NIH officials reasoned that once the government owned patents on
gene fragments, it could grant licenses to biotechnology companies,
thus creating a stable climate in which to invest in further research:
By first obtaining a patent, the government can then license it to
companies to use the gene to develop a drug or "socially responsi-
ble" product. The patent will give the licensee the security to in-
vest considerable resources into developing the product . . .
something that wouldn't be possible if they simply published their
findings without patent protection. 179
2. United States Taxpayers Benefit From Patents
Since the United States human genome projects are partially
funded by United States taxpayers, the NIH believed that not applying
for patents on its discoveries "would cause American taxpayers and
biotech companies to lose out on the wealth expected to flow from a
cascade of genetic discoveries."' 80 While ensuring that taxpayers ben-
efit from the NIH's research is a sound policy objective, it is not clear
that allowing the NIH to claim patents on partial gene sequences
would further that goal. As Eisenberg points out, "[t]he amount of
federal funding for the Human Genome Project is trivial compared to
the amount of private funding for biotechnology research and develop-
ment.""' If the NIH patents would have created strong disincentives
to research genes on which the NIH held a partial patent, as critics
contended, then the overall effect of the NIH's efforts would be ad-
verse to United States taxpayers.
3. Technology Transfer Issues
Under the Federal Technology Transfer Act, Dr. Venter would
have been entitled to retain title to the gene fragments when he left the
NIH if the NIH had decided not to file the applications.' 82 Therefore,
178. Stout, supra note 169, at BI.
179. Id
180. Waldholz & Stout, supra note 126, at Al.
181. Eisenberg, supra note 75, at 721, 736.
182.
If a Federal agency which has the right of ownership to an invention under this
chapter does not intend to file for a patent application or otherwise to promote
commercialization of such invention, the agency shall allow the inventor, if the
inventor is a Government employee or former employee who made the invention
during the course of employment with the Government, to retain title to the inven-
tion (subject to reservation by the government of a nonexelusive, nontransferable,
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the NIH's decision may have been a proper means of ensuring that the
government retained title to the fragments. However, as Eisenberg
notes, "current regulations of the Department of Health and Human
Services require that [the NIH] allow employees, such as Dr. Venter,
to pursue such rights on their own."1"3 Given the fact that Dr. Venter
may not have been able to pursue his own patent on the sequences, it
seems clear that the government's decision to seek patents was moti-
vated more by the potential loss to taxpayers and the United States
biotechnology industry than by the need to retain title to the gene
fragments.
C. Policy Arguments Against the NIH
While the NIH sought to promote a "socially responsible" means
of encouraging the discovery of useful biotechnology-related inven-
tions, critics of the NIH argued that seeking patents on such fragments
actually threatened the progress of the biotechnology industry. The
following section presents and analyzes each of the critics' arguments
in turn.
1. Reduced Collaboration
According to the 1988 Office of Technology Assessment study:
"Mapping genes, both human and nonhuman, has been an interna-
tional effort since its inception. International agreements for databases
(particularly those containing DNA sequence data) and collaborations
on gene mapping (notably the Center for the Study of Human Poly-
morphism in Paris) have been in operation for several years." 184
Awarding patents on cDNAs to either public or private sector entities
would arguably undermine collaboration among scientists working on
human genome projects. According to the ASHG,
The primary concern is that the Human Genome Project should be
a project of international collaboration. It should not be a competi-
tion between laboratories and between countries to see who can
"own" the largest portion of the human genome. HUGO, the inter-
national Human Genome Organization, has stated this principle
since its inception in 1988. The patenting of ESTs clearly and un-
equivocally contradicts this principle. There is no question that the
patenting of ESTs by the NIH group, or by anyone else, will pre-
irrevocable paid-up license to practice the invention of have the invention prac-
ticed throughout the world by or on behalf of the Government)...
15 U.S.C. § 3710(d).
183. Rebecca S. Eisenberg, Genes, Patents, and Product Development, 257 ScruNca 903
(1992).
184. MAPPING OuR GENEs, supra note 1, at 8.
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cipitate a race to isolate ESTs in many countries, a race to patent
throughout the world and a race to exploit the genome information
for all its "worth". It is virtually certain that under such conditions
the information would not be shared between competing groups un-
til after patents are secured, so that duplication of effort will be
impossible to avoid. 185
The NIH's efforts may have already adversely affected collabora-
tion by causing researchers to wonder how patent law affects their
research. According to Science News,
Critics of large-scale EST patenting contend that it has already un-
dermined science by sowing secrecy and impeding the rapid ex-
change of data that could speed gene mapping and discovery.
[Keith] Gibson [head of the London-based Medical Research
Council's Human Genome Mapping Project] cites his own experi-
ence, saying that [his organization] postponed the release of more
than 1,000 tag sequences for a year while tangling with the United
States and European patent systems. Concern over patenting "has
held up and continues to hold up the exchange of information," he
says. "Scientists want to be reassured that no patent issues are
involved.' 8 6
Dr. Harold Varmus, the new Director of NIH, was acutely aware
of the critics' charge that allowing patents on cDNA fragments would
reduce collaboration. In fact, this concern probably was the major rea-
son why the NIH decided to abandon its attempt to gain patents on the
Dr, Venter sequences. According to Dr. Varmus, "I do not believe
that patenting at this stage promotes technology development, and it
may impede more important research collaborations here and
abroad."'8 7
Although the question of whether cDNA fragments can be pat-
ented remains unresolved due to the NIH's abandonment of its appli-
cations, Dr. Francis Collins, the current director of the United States
human genome project, hopes that the decision might "improve the
scientific atmosphere" by relieving pressure to patent.' 8 8 However,
private companies intend to pursue patents on cDNA fragments; there-
fore, it seems unlikely that information on genetic discoveries will be
freely and openly shared.
Given the fact that more and more genomic research is funded by
private companies rather than the NIH, researchers in this area may
185. ASHG PosrnoN PAmR, supra note 157, at 2.
186. Wuethrich, supra note 7, at 155.
187. Waldholz, supra note 105, at BI.
188. Id.
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feel increasing pressure to keep research secret until a patent issues,
rather than release it into the public domain. For example, Dr. Venter
left his position as Chief of Receptor Biochemistry of the National
Institute of Neurological Disorders and Stroke in Bethseda on July 13,
1992, taking 30 of NIH's investigators with him. Dr. Venter's deci-
sion "essentially [took] the NIH out of the business of spewing out
sequences of gene pieces." ' 9 Dr. Venter became the director of The
Institute for Genomic Research (TIGR) in Germantown, Maryland, a
non-profit research institution funded entirely by Human Genome Sci-
ences (HGS). HIGS has provided TIGR with a $70 million, ten-year
grant in return for all "exclusive worldwide rights to information and
materials TIGR produces."19 HGS was formed by Healthcare Invest-
ment Corporation, a venture-capital firm. Wallace Steinberg, chair-
man of Healthcare, intends to be "socially responsible with his
investment in Dr. Venter's work" -nd plans to "promptly publish" any
"genetic information" uncovered by Dr. Venter and "collaborate freely
with other companies and with the NIH. 1 1 Mr. Steinberg also noted
that other countries were "garnering gene fragments," but had made
no commitment to publish their researchers' discoveries.19 2 If Mr.
Steinberg follows through on his promise, even though his vow may
prevent TIGR from obtaining valuable patents, then researchers
should be able to use TIGR's research freely to assist them inmaking
scientific progress. However, as the Wall Street Journal notes, "HGS
has been criticized for keeping this vast store of sequence data se-
cret."19 Any refusal by HGS to disclose information may have a del-
eterious effect on future research because, according to Dr. William
Haseltine, the founder of HGS, "We're finding 300 to 400 new genes
per day." 194
2. Artificial Tollbooth
The biotechnology industry is risky: only one-fifth of 1990 bio-
technology companies surveyed were profitable.195 Therefore, pat-
ents, which confer valuable commercial rights, are essential to ensure
that certain products are developed. Without patent protection, the
189. Kolata, supra note 85, at Cl.
190. Wuethrieh, supra note 7, at 156.
191. L
192. Id.
193. Jerry E. Bishop, Human Genome Sciences Sees Gold in Trove of Genes, WALL ST. J.,
March 18, 1994, at B4.
194. L
195. OrCE OF TscNw ovy Assassrmr, U.S. CONGRESS, BioTECHNGLOOY IN A GLOBAL
ECONOMY 6 (1992).
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billions of dollars needed to bring a biotechnology product to the mar-
ket may not be available.' 96 However, not all products are worthy of a
patent. In fact, granting a patent early in the discovery process may
impede later research. Critics of the NIH's now-abandoned patent
policy argued that patenting cDNA fragments of unknown origin and
location threatened to create a tollbooth that would impede useful re-
search. According to patent attorney Michael Roth, "Instead of pav-
ing the road to further advances in science, NIH has erected a
tollbooth along the way by filing for a patent." 197 If private compa-
nies, such as HGS, succeed in their attempts to patent gene fragments,
then private companies may charge a very high price for the use of
"their" partial sequences. Obviously, the use of patents in this manner
would undermine the search for socially useful biotechnology prod-
ucts and would thus violate the policy objectives underlying the patent
system.
3. Uncertainty Created by Patents
If the fragments of genes are patented, then it is possible that
later, more important discoveries, such as the full gene sequence or the
protein associated with the gene fragment, may not be patentable on
the ground that the prior patent made the discoveries obvious. Fur-
thermore, since applicants often claim as many different patents as
they can arising out of the same research, it is possible that companies
will submit applications claiming not only the partial sequence but the
entire gene as well. Since it may take years for the PTO to rule on a
typical biotechnology patent, companies may choose not to research
because they are uncertain whether the PTO will grant a patent that
covers prospective areas of research. Furthermore, since the applica-
tions are not publicly released, it may be impossible to determine ex-
actly which genes or gene fragments are being sought to be patented.
If patents issue on gene fragments, additional uncertainty may be
caused by the fact that several companies end up holding patent rights
to different portions of the same gene. In this case researchers may
have to approach each company and negotiate a royalty arrangement.
Obviously, such negotiations may increase transaction costs and will
result in much less research being done. Such cost increases may have
a significant impact on the biotechnology industry, which is relatively
196. Id ("As much as $5 to $10 billion may be needed just to develop the 100 biotechnol-
ogy products currently in human clinical trials.").
197. Supra note 153, at 75.
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new, small, and exceptionally sensitive to any perturbation in its eco-
nomic, development.19
4. Overloads at the PTO
According to Professor Rebecca Eisenberg, "Given the current
[late 1990] backlog of biotechnology patent applications in the PTO, a
patent applicant may have to wait four to five years before the patent
examiner reaches a final decision on whether to issue a patent." 199
Given that some companies have stockpiled thousands of cDNA frag-
ments and are primed to file their patent applications now that the NIH
has refused to do the work for them, it seems that the PTO faces the
possibility of being swamped by an avalanche of applications on gene
fragments unless Congress takes action. For example, as previously
discussed, Incyte Pharmaceuticals is preparing to sequence approxi-
mately 100,000 gene fragmeits a year beginning in the spring of 1994.
Furthermore, as a recent article in Science News recognized, develop-
ments in technology in genome research are "[s]o fast and furious ...
that within several years, patents may have beenfiled for every one of
the estimated 100,000 genes nestled in human cells . . ." While
these applications may befiled, no one can possibly guess how long it
will take to process all of them. Meanwhile, important research may
be postponed due to uncertainty concerning which company or com-
panies owns a patent on which portion of the human genome.
VII. LEGISLATIVE REMEDIES
Although the PTO, the Court of Appeals for the Federal Circuit,
and the Supreme Court play a significant role in evaluating whether
biotechnology-related products are patentable, ultimately, it is Con-
gress that has the responsibility of ensuring that the patent system is
functioning correctly. The Supreme Court recognized its technical
limitations in the Chakrabarty decision and also recognized that Con-
gress should be responsible for resolving the complex competing so-
cial considerations raised in the field of biotechnology. 0 1 Therefore,
since the Office of Technology Assessment is due to present a com-
prehensive study to Congress on the issue of patenting DNA se-
quences in the late summer of 1994, Congress should take action on
198. Dan L. Burk, Biotechnology and Patent Law: Fitting Innovation to the Procnstean
Bed, 17 Ru-rms CoMpurER & TFCH. LJ. 1, 24 (1991).
199. Eisenberg, supra note 75, at 740 (emphasis added).
200. Wuethrich, supra note 7, at 155.
201. See Kiley, supra note 171, at 920 (providing an illuminating discussion of the role of
the U.S. Supreme Court in the regulation of biotechnology).
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this issue. The following section reviews several courses of action
open to Congress that have been proposed by critics of the NIH.
A. Define Utility
Congress should amend the Patent Act to provide a definition of
"useful." Following the Brenner v. Manson decision, Congress should
define useful as follows: the term "useful" means that the invention
has "substantial and specific utility that is in currently deliverable
form.""2 2 By codifying the Brenner standard, Congress would eradi-
cate the possibility that companies could obtain a patent on a gene
fragment without knowing "what it is, much less what it will be used
for." As Thomas Kiley points out,
The patent system is abused [when] those who would benefit...
from the later labors of others can posit patents on the most strained
utilities imaginable. Typical is the suggestion by NIH that organ
differentiation is sufficient utility for a patent reaching to dominate
the later discovery by others of a life-saving application for a
cDNA.2 °3
B. Moratorium on Patenting'Life Forms?
Another approach would be for Congress to re-establish the
"products of nature" doctrine by passing a law banning the patenting
of any life form. Senator Mark Hatfield (Republican from Oregon)
proposed a moratorium on the issuance of patents for "human tissue,
fluid, cell, gene, or gene sequences" as an amendment to the NIH
Reauthorization Act of 1991. 4 While such a moratorium would cre-
ate a bright-line rule that would be easy for courts to apply, a ban on
such patents might destroy the United States biotechnology industry,
which is projected to have world-wide sales in excess of $100 billion
by the year 2000.205 As Thomas Kiley argues, "[i]t would be a flat
mistake to urge Congress... to now say that DNA or other natural
products should be unpatentable even after they have been isolated...
lest we eliminate patent incentives for the development of important
medicines."205
202. 1d&
203. 1d. at 910.
204. Docherty, supra note 63, at 540.
205. David T. Kingsbury, The Regulatory "Coordinated framework" for Biotechnology, 4
BIo1Ec. 1021, 1072 (1986).
206. Kiley, supra note 171, at 913.
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C. A Special Intellectual Property System for Biotechnology?
As discussed in section V.A, infra, Congress has created a sepa-
rate system of property rights for novel plant varieties20 7 and semicon-
ductor chip masks.20 8 It may be appropriate for Congress now to
create a specialized intellectual property system for the products of
biotechnological research.2"
1. Towards a System of "Known Uses"
It may be possible to avoid the problems of gene "ownership" by
restricting patents to "known uses."210 For example, Dr. Leroy Hood,
the head of the University of Washington's department of molecular
biology and the founder of Applied Biosystems in Foster City, Cali-
fornia, is working on a patent application with the assistance of the
DOE. Dr. Hood's research team has been "sequencing the genes en-
coding the beta chain of the human T cell receptor. '21 1 While a broad
patent application could conceivably cover "not only the techniques
for diagnosing autoimmune diseases but also... anything involving T
cell activity," Dr. Hood's application will only claim "the specific
uses of developing the diagnostic and therapeutic tools for dealing
with specific autoimmune diseases. 212
A system allowing the patenting only of known uses would com-
port with the goal of rewarding the inventor for the value of the contri-
bution made to society.213
2. Change the Obviousness Requirement
As more scientific knowledge is thrust into the public domain, it
becomes more likely that a biotechnology "discovery" will be deemed
obvious under section 103. The NIH was acutely aware of the possi-
bility that further discoveries based on Dr. Venter's gene fragments
would be deemed obvious if Dr. Venter were allowed to publish his
207. The Plant Variety Protection Act of 1970, Pu. L. No. 91-577, 84 Stat. 1542 (codified
as amended at 7 U.S.C. §§ 2321-2522 (1988)).
208. The Semiconductor Chip Protection Act of 1984, Pun. L. No. 98-620, 98 Stat. 3347
(codified as amended at 17 U.S.C. §§ 901-914 (1988)).
209. But see Al Gore, Planning a New Biotechnology Policy, 5 HARv. J. L. AND TECH. 19,
25 (1991) (arguing that the law should focus on making biotechnology research freely available
and on providing safeguards against illegal uses of biotechnology, rather than on defending intel-
lectual property rights).
210. Christopher Anderson, A New Model for Gene Patents, 260 ScLENcE 23, 24 (1993).
211. Id. at 24.
212. Id.
213. See Greenfield, supra note 113, at 1060 ("The patent system, by giving a patentee a
temporary monopoly over her invention, acknowledges and rewards the inventor's contribution
to society.").
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findings before the NIH filed its patent applications. According to the
Wall Street Journal, "The NIH... was worried that [publishing se-
quencing information] might jeopardize the possibility of obtaining
patents later, when the function of the genes is known." '14
Dr. Venter has proposed a solution to the dilemma caused by
section 103's non-obviousness requirement. He would amend the sec-
tion by adding the following language: "Prior art shall not preclude
patentability of an amino acid [sequence] or nucleotide sequence
solely because such prior art discloses a portion of such sequence." 215
D. Research Exemption
35 U.S.C. § 271(a) provides that "whoever without authority
makes, uses or sells any patented invention, within the United States
during the term of the patent therefor, infringes the patent."21 6 Some
commentators have argued that Congress create an "experimental use
exception" to section 271(a) in order to promote basic research. In
fact, the House Committee of the Judiciary stated in 1988 that "Con-
gress should, at some future point, amend title 35 of the Patent Act to
provide that use of a patented invention or process is not an act of
infringement if done for the purpose of experimentation or
research." 217
If patents were to issue on gene fragments, then an experimental
use exception would allow researchers to continue to use the known
fragments in experiments to discover the full gene. According to Pro-
fessor Rebecca Eisenberg, "An experimental use exemption from in-
fringement liability could prevent patents from burdening the progress
of research science while still preserving incentives for private invest-
ment in research and development in biotechnology. This might be a
better solution to the conflict between patent law and scientific norms
than denying patent protection entirely in fields where basic science
and commercial interests converge."218
E. International Agreement
The NIH could attempt to reach an international agreement with
foreign governments and their research grantees to the effect that no
214. Hilary Stout, Gene-Fragment Patent Request Is Turned Down, WALL ST. J., Sept. 23,
1992, at BI.
215. Patents, Senate Subcommittee Hearing Focuses on Rejection of NIH Gene Patent Re-
quests, BNA DAILY RmORT FOR EXECtTVES, Sept. 24, 1992, at 188.
216. 35 U.S.C. § 271(a)(1992).
217. TRANsGEmc ANuMAL PATENT REFORM AcT, H. REP. No. 4970, 100th Cong., 2d Sess.
at 51 (1988).
218. Eisenberg, iupra note 75, at 742.
COMPUTER & HIGH TECHNOLOGY LAW JOURNAL [
patents will be sought on DNA sequences of unknown biological ac-
tivity. Over 200 scientists from around the world have already signed
a declaration calling for the results of genome research to remain in
the public domain.219 While such an agreement would have the salu-
tary effect of restoring collaboration between nations, it may not affect
private sector research. As previously discussed, private companies in
the United States and Japan already possess extensive libraries of
cDNA fragments and have already filed or will soon file patent appli-
cations. Therefore, an international agreement may have little effect
on the current patent situation.
VIII. CONCLUSION
The goal of United States patent law is to encourage the produc-
tion of socially beneficial inventions. Allowing patents on cDNA
fragments would only hold up research; therefore, patents should not
issue as a matter of public policy. While there are moral and philo-
sophical reasons for not allowing patents on fully identified genes, 220
awarding such patents would serve the policy goal underlying the pat-
ent system because such "discoveries" are truly useful. While the line
between a fully identified gene and a partially identified gene may be
difficult to draw, it is vital that Congress take action to recognize the
distinction between useful and non-useful products of biotechnology
research by defining utility, creating a special intellectual property
system for biotechnology, changing the obviousness requirement, cre-
ating a research exemption, and/or reaching a meaningful international
agreement.
219. Docherty, supra note 63, at 532.
220. Maebius, supra note 170, at 651 n.2 (citing Geneticists and Religious Leaders Ponder
Implications of the Human Genome Project, GEm=ic ENG'o NEws, April 15, 1992, at 29).
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